Cumberland Pharmaceuticals Inc Overview
Pro stress-test →Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company with a portfolio of FDA-approved brands that delivered combined net revenues of $9.1 million in Q1 2026. The company is undergoing a strategic transformation, having announced a definitive agreement to sell its FDA-approved U.S. branded portfolio for $100 million cash to Apotex, subject to shareholder approval and intended to refocus Cumberland on development-stage programs.
Strategic Profile
Pro stress-test →The company's branded product portfolio includes Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, Vibativ, and Talicia, serving hospital acute care, gastroenterology, and oncology segments. Cumberland is advancing Phase II studies of ifetroban in systemic sclerosis, Duchenne cardiomyopathy, and idiopathic pulmonary fibrosis.
Competitive Landscape
Pro stress-test →Cumberland competes in specialty pharmaceuticals across hospital acute care, gastroenterology, and oncology with branded products. Key competitors include larger specialty pharma companies and generic manufacturers offering similar therapies (pain management, nausea, infection treatment). In development programs, Cumberland's ifetroban competes against other candidates for rare/orphan indications including systemic sclerosis and pulmonary fibrosis.
Industry Context
Cumberland Pharmaceuticals Inc operates in Specialty pharmaceuticals—hospital acute care and gastroenterology.
Key facts
Founded: 1999 · Headquarters: Nashville, Tennessee · Employees: N/A · Revenue: $9.1M (Q1 2026); $36.6M estimated annualized · Market cap: N/A